Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Ovarian Epithelial Tumor — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm
Ovarian Epithelial Tumor

Cancer Family

Ovarian Epithelial Tumor

CI-CAN-00000305Explore in graph →

Non-malignant271 active trials2 approved drugs26 evidence items

NCIt: C4381
OncoTree: OVT
UMLS CUI: C0341823

Overview
Statistics
Survival
Genomics9
Variants & evidence26
Drugs17
Trials900
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (25)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–25 of 25 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
· N Engl J Med · 2016 · PMID 27717299 · validated civic_curation pubmed
Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.
· Nat Genet · 2014 · PMID 24658004 · validated cbioportal_study pubmed
Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
· Cancer · 2010 · PMID 20336784 · validated civic_curation pubmed
Aurora kinases as prognostic biomarkers in ovarian carcinoma.
· Hum Pathol · 2009 · PMID 19157502 · validated civic_curation pubmed
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
· JAMA · 2012 · PMID 22274685 · validated civic_curation pubmed
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
· Oncogene · 2012 · PMID 22139083 · validated civic_curation pubmed
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
· Oncotarget · 2016 · PMID 26625204 · validated civic_curation pubmed

Showing 1–25 of 25 publications

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.

· Clin Cancer Res · 2014 · PMID 24240112 · validated civic_curation pubmed

Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.

· J Ovarian Res · 2016 · PMID 27209210 · validated civic_curation pubmed

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.

· J Clin Oncol · 2020 · PMID 32822286 · validated civic_curation pubmed

ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.

· Gynecol Oncol · 2019 · PMID 30797591 · validated civic_curation pubmed

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

· J Clin Oncol · 2015 · PMID 26324360 · validated civic_curation pubmed

Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.

· Invest New Drugs · 2015 · PMID 26490654 · validated civic_curation pubmed

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.

· JCO Precis Oncol · 2024 · PMID 38603650 · validated civic_curation pubmed

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.

· Clin Cancer Res · 2015 · PMID 25370471 · validated civic_curation pubmed

Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report.

· Gynecol Oncol Rep · 2019 · PMID 30809568 · validated civic_curation pubmed

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

· Cancer Res · 2014 · PMID 24240700 · validated civic_curation pubmed

Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.

· Br J Cancer · 2014 · PMID 25010864 · validated civic_curation pubmed

Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.

· Carcinogenesis · 2013 · PMID 23764753 · validated civic_curation pubmed

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

· Clin Cancer Res · 2017 · PMID 27663592 · validated civic_curation pubmed

Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR.

· Nat Commun · 2025 · PMID 40169546 · validated civic_curation pubmed

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

· Mol Oncol · 2013 · PMID 23415752 · validated civic_curation pubmed

Elkin et al. NPJ Genome Med 2021

· 2021 · PMID 34819508 · validated cbioportal_study pubmed

Manning-Geist et al. Clin Cancer Res. 2022

· 2022 · PMID 35443055 · validated cbioportal_study pubmed

TCGA, Nature 2011

· 2011 · PMID 21720365 · validated cbioportal_study pubmed